InvestorsHub Logo
Followers 95
Posts 4214
Boards Moderated 1
Alias Born 11/05/2014

Re: None

Tuesday, 11/28/2023 12:09:47 AM

Tuesday, November 28, 2023 12:09:47 AM

Post# of 165
NeuroSense Webinar with Emerging Growth Conference - October 4, 2023

https://www.youtube.com/watch?v=ZLL_QdiepMo





Besides their highly expected great results from ALS Phase 2b trial to be released in December, they also have started the Phase 2 trial for Alzheimer's disease with very positive results from the phase 1 trial. As the CEO said on November 7, 2023, "In December, NeuroSense will unvail the clinical Top-line results of the Paradigm study (phase 2b trial), marking a major turning point in the fight against ALS. We are committed to sharing all results from this groundbreaking clinical trial with the ALS community." This company will be huge.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NRSN News